EP Patent

EP2391358A1 — Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists

Assigned to Wisconsin Alumni Research Foundation · Expires 2011-12-07 · 14y expired

What this patent protects

A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amo…

USPTO Abstract

A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2391358A1
Jurisdiction
EP
Classification
—
Expires
2011-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Wisconsin Alumni Research Foundation
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.